When solely assessing the ER-positive patient group, the median PFS and median OS from our study compared significantly unfavourably, especially in studies evaluating CDK4/6-inhibitors and/or endocrine therapy as first-line treatment for ER-positive advanced breast cancer [3, 17, 26–34]. This evidence concerns the gene ESR1 and breast cancer.